During a recent meeting, health ministers from several African countries expressed an urgent need to strengthen local drug production. This meeting comes at a time when Africa heavily relies on imports, accounting for over 70% of the medicines it uses, primarily from India and China.

“Our pathogens must first be fought by our own scientists and our own manufacturers,” stated H.E. Dr. Jean Kaseya, regional director of Africa CDC. His remarks underscore the importance of health sovereignty that would allow the continent to better manage its public health needs.

The attending ministers agreed that local production could not only improve access to treatments but also reduce vulnerability to global health crises. A statement released after the meeting indicates that participants wish to establish a regulatory framework conducive to the local pharmaceutical industry. This would include investments in research and development as well as partnerships with the private sector to stimulate innovation.

Furthermore, the World Health Organization (WHO) has recently selected six African countries—South Africa, Kenya, Nigeria, Senegal, Egypt, and Tunisia—to develop their capacity to produce messenger RNA vaccines. This decision is seen as a step towards greater autonomy in public health.

However, challenges remain significant. As reported by a dispatch from Afro.WHO, African countries must overcome obstacles such as insufficient funding and inadequate infrastructure to implement these ambitions.

As the continent continues to face the aftermath of the Covid-19 pandemic, this collective will could mark a turning point in how Africa approaches its health. The next step will be to transform these discussions into concrete actions that will directly benefit local populations.